Jayasinghe, R, Cao, S, Gao, Q, Wendl, MC, Vo, NS, Liu, Y, Zhang, W, Akbani, R, Broom, BM, Ju, Z, Kanchi, RS, Korkut, A, Li, J, Liang, H, Ling, S, Liu, W, Lu, Y, Mills, GB, Uppore Kukkillaya, AR, Weinstein, JN, Zhang, J, Liu, X, Wang, L , Carvalho, AL, Fregnani, JG, Reis, RV, Scapulatempo, CN, Ajani, JA, Behrens, MC, Bondaruk, J, Broaddus, R, Czerniak, BA, Esmaeli, B, Fujimoto, J, Gershenwald, JE, Guo, CC, Lazar, A, Logothetis, CJ, Meric-Bernstam, F, Moran, C, Ramondetta, LM, Rice, DC, Sood, AK, Tamboli, P, Thompson, T, Troncoso, P, Tsao, A, Wistuba, II, von Deimling, A, Chen, K
Phase II Clinical Trials These promising preclinical findings led to Phase I and Phase II clinical trials in humans
By resisting binding to IGF-binding proteins (IGFBPs), IGF-1 LR3 remains free in the bloodstream longer, which increases its ability to activate IGF-1 receptors in muscle tissue
Key Benefits: Boosts Energy Levels: L-carnitine and CoQ10 work synergistically to enhance energy production and reduce fatigue
Reduced L-glutathione (GSH) supplied in a phospholipid vesicle format the Helix Liposomal delivery system used in select Codeage formulations
